P778: LONG-TERM UTILIZATION AND BENEFIT OF LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) FROM THE MEDALIST TRIAL

• P. Fenaux,
• V. Santini,
• R. S. Komrokji,
• A. Zeidan,
• G. Garcia-Manero,
• R. Buckstein,
• D. Miteva,
• K. Keeperman,
• N. Holot,
• J. Zhang,
• J. A. Nadal,
• B. Rosettani,
• A. Yucel,
• U. Platzbecker

Affiliations

P. Fenaux

1 Service d’Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris and Université Paris 7, Paris, France

V. Santini

2 MDS Unit, AOU Careggi, University of Florence, Florence, Italy

R. S. Komrokji

3 Moffitt Cancer Center, Tampa

A. Zeidan

4 Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, New Haven

G. Garcia-Manero

5 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, United States of America

R. Buckstein

6 Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Canada

D. Miteva

7 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

K. Keeperman

8 Bristol Myers Squibb, Princeton, United States of America

N. Holot

8 Bristol Myers Squibb, Princeton, United States of America

J. Zhang

8 Bristol Myers Squibb, Princeton, United States of America

J. A. Nadal

7 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

B. Rosettani

7 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland

A. Yucel

8 Bristol Myers Squibb, Princeton, United States of America

U. Platzbecker

9 Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany